| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
42,110,000 |
| Market
Cap: |
816.93(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.93 - $20.72 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 556 |
| Guru Rank Value : 3.3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile roGen Pharma is a biopharmaceutical company focused on developing and commercializing solutions that treat urothelial and specialty cancers. Co.'s approved product Jelmyto® (mitomycin) for pyelocalyceal solution, and its investigational candidate, UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer, respectively. In addition, Co.'s immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
27,833 |
27,833 |
42,143 |
80,660 |
| Total Sell Value |
$457,467 |
$457,467 |
$621,498 |
$1,202,746 |
| Total People Sold |
2 |
2 |
2 |
2 |
| Total Sell Transactions |
4 |
4 |
8 |
15 |
| End Date |
2025-05-22 |
2025-02-18 |
2024-08-20 |
2023-08-21 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schoenberg Mark |
Chief Medical Officer |
• • – |
2025-08-11 |
4 |
S |
$17.69 |
$176,900 |
D/D |
(10,000) |
148,229 |
|
-8% |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2025-07-28 |
4 |
S |
$19.14 |
$98,552 |
D/D |
(5,149) |
158,229 |
|
-4% |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2025-07-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
163,378 |
|
- |
|
| Smith Jason Drew |
General Counsel |
• • – |
2025-07-28 |
4 |
S |
$19.14 |
$143,971 |
D/D |
(7,522) |
41,492 |
|
-4% |
|
| Smith Jason Drew |
General Counsel |
• • – |
2025-07-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,500 |
49,014 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2025-06-09 |
4 |
S |
$7.37 |
$38,044 |
D/D |
(5,162) |
153,378 |
|
-181% |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2025-06-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
158,540 |
|
- |
|
| Smith Jason Drew |
General Counsel |
• • – |
2025-01-31 |
4 |
S |
$11.14 |
$82,202 |
D/D |
(7,379) |
32,514 |
|
34% |
|
| Smith Jason Drew |
General Counsel |
• • – |
2025-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,667 |
35,281 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2025-01-31 |
4 |
S |
$11.14 |
$50,698 |
D/D |
(4,551) |
148,540 |
|
34% |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2025-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,000 |
150,436 |
|
- |
|
| Kim Dong |
Chief Financial Officer |
• • – |
2024-09-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
37,753 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2024-09-09 |
4 |
S |
$13.08 |
$11,236 |
D/D |
(859) |
145,091 |
|
23% |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2024-09-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,666 |
145,950 |
|
- |
|
| Smith Jason Drew |
General Counsel |
• • – |
2024-09-09 |
4 |
S |
$13.08 |
$19,895 |
D/D |
(1,521) |
25,226 |
|
23% |
|
| Smith Jason Drew |
General Counsel |
• • – |
2024-09-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,333 |
26,747 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2024-06-10 |
4 |
S |
$13.08 |
$67,401 |
D/D |
(5,153) |
144,284 |
|
0% |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2024-06-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
149,437 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2024-03-18 |
4 |
S |
$14.05 |
$168,600 |
D/D |
(12,000) |
139,437 |
|
-11% |
|
| Smith Jason Drew |
General Counsel |
• • – |
2024-02-01 |
4/A |
S |
$15.78 |
$78,790 |
D/D |
(4,993) |
23,414 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2024-02-01 |
4/A |
S |
$15.78 |
$59,790 |
D/D |
(3,789) |
151,437 |
|
- |
|
| Kim Dong |
Chief Financial Officer |
• • – |
2024-01-31 |
4/A |
OE |
$0.00 |
$0 |
D/D |
3,333 |
35,253 |
|
- |
|
| Smith Jason Drew |
General Counsel |
• • – |
2024-01-31 |
4 |
S |
$15.74 |
$78,590 |
D/D |
(4,993) |
23,414 |
|
17% |
|
| Smith Jason Drew |
General Counsel |
• • – |
2024-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
26,742 |
|
- |
|
| Schoenberg Mark |
Chief Medical Officer |
• • – |
2024-01-31 |
4 |
S |
$15.74 |
$59,639 |
D/D |
(3,789) |
151,437 |
|
17% |
|
174 Records found
|
|
Page 1 of 7 |
|
|
0.31 (1.57%) 
